PubMed Health⌕ Search

PubMed · 11445960

A robust multi-syringe system for process flow analysis. Part 3. Time based injection applied to the spectrophotometric determination of nickel(II) and iron speciation.

Abstract

A new software-controlled time-based system for sample or reagent introduction in process flow injection analysis was developed. By using a multi-syringe burette coupled with one multi-port selection valve, the time-based injection of precise known volumes was accomplished. Characteristics and performance of the injection system were studied by injecting an indicator in a buffered carrier. Two multi-syringe time-based injection (MS-TBI) systems were implemented: first, the injection of a sample in a multiple-channel manifold where the sample would sequentially merge and react with different reagents, and second, the sequential injection of several solutions (sample and reagents) into a particular flowing stream. The first system was applied to the spectrophotometric determination of nickel(II) in diluted samples from the acidic nickel ore leaching process, by using ammonium citrate as carrier, a saturated solution of iodine as oxidizing agent and alkaline dimethylglyoxime as chromogenic reagent. The sampling frequency attained was 57 h-1. Determinations on process samples compared well at the 95% confidence level with the reference values obtained by ICP-OES. The second time-based injection system was applied to the speciation of iron. Total iron and iron(II) concentrations were separately and sequentially determined using 1,10-phenanthroline in acetic buffer medium as reagent. The developed manifold allowed the optional use of two different carrier solutions, containing or not containing ascorbic acid, for performing the separate determinations. Also, in the sequential procedure, plugs of reducing carrier were alternatively intercalated before the sample injections used for total iron determinations. Sampling frequencies of 68 injections per hour were routinely used. Accuracy was assessed by analyzing synthetic known mixtures of Fe(III) and Fe(II) standard solutions. Recoveries of 98-100.5% with a maximum relative standard deviation of 3.6% were found. Results obtained for various samples of fertilizers agreed well with those attained by the standard batch procedure.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Albertús, A Cladera, E Becerra, V Cerdà. 2001. A robust multi-syringe system for process flow analysis. Part 3. Time based injection applied to the spectrophotometric determination of nickel(II) and iron speciation.. https://doi.org/10.1039/b007569h

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗